Literature DB >> 343487

Long term prognosis of infants with severe idiopathic respiratory distress syndrome. II. Cardio-pulmonary outcome.

J Kamper.   

Abstract

75 out of 77 children surviving IRDS with the aid of intermittent positive pressure ventilation have been followed up by age 2.6-7.6 years together with 68 matched controls. The morbidity of lower respiratory tract illnesses was significantly higher in IRDS survivors than in controls affecting a total of 48%, half whom were admitted to hospital on at least on occasion. Only 3 IRDS survivors had pneumonias beyound their third year, however. One child suffered from a moderate stridor due to a partial laryngeal stenosis and one from some dyspnoea at function caused by broncho-pulmonary dysplasia. Thoracic X-ray changes were found significantly more often and more marked in IRDS survivors but on the whole the changes were discrete. Neither the occurrence of pneumonia nor X-ray changes in the IRDS survivors were statistically relatable to a number of neonatal or therapeutical characteristics. Measurements of heart volume, respiratory frequency, oxygen saturation and acid-base values did not differ between the groups. Ventilated IRDS survivors, even with some degree of radiographic demonstrable residua, thus seem to have a good long-term prognosis with regard to lung function, irrespective of a preliminary high morbidity of lower respiratory tract illnesses.

Entities:  

Mesh:

Year:  1978        PMID: 343487     DOI: 10.1111/j.1651-2227.1978.tb16279.x

Source DB:  PubMed          Journal:  Acta Paediatr Scand        ISSN: 0001-656X


  2 in total

1.  Respiratory symptoms in children of low birth weight.

Authors:  K N Chan; A Elliman; E Bryan; M Silverman
Journal:  Arch Dis Child       Date:  1989-09       Impact factor: 3.791

2.  Pulmonary sequelae of neonatal respiratory distress in very low birthweight infants: a clinical and physiological study.

Authors:  Y C Wong; C S Beardsmore; M Silverman
Journal:  Arch Dis Child       Date:  1982-06       Impact factor: 3.791

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.